MedTrace Logo

Smoking Cessation Using Motivational Therapy and Varenicline

NCT00701896 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 294

Last updated 2021-01-15

Study results available
· View outcomes & findings →

Summary

People that are infected with HIV appear to be especially susceptible to the adverse effects of cigarette smoking. The purpose of this study is to determine if quitting smoking by using a specialized smoking cessation treatment can prevent one from developing accelerated lung damage, particularly emphysema.

Conditions

  • Smoking
  • HIV Infections

Interventions

DRUG

Varenicline tartrate

1 mMg tablet form; daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12.

DRUG

Nicotine Replacement Therapy

Nicotine gum and nicotine patch

OTHER

Biological Control

No treatment intervention only information and procedures.

BEHAVIORAL

Motivational Interview

60 minute one-on-one Interview

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Philip Diaz

    lead OTHER

Principal Investigators

  • Philip T. Diaz, MD · Ohio State University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-03
Primary Completion
2013-04-20
Completion
2013-06-20

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00701896 on ClinicalTrials.gov